tetano
Editor, Senior Moderator
Cureus
. 2022 Nov 30;14(11):e32078.
doi: 10.7759/cureus.32078. eCollection 2022 Nov.
Rapid Resolution of Post-COVID-19 Inflammatory Syndrome in an Adult With Targeted Inhibition of Interleukin-1B
Mario Felix[SUP] 1 [/SUP], Larabe Farrukh[SUP] 2 [/SUP], Simple Modi[SUP] 3 [/SUP], Ruben Peredo-Wende[SUP] 4 [/SUP]
Affiliations
Abstract
Multisystem inflammatory syndrome (MIS) is a severe inflammatory response that occurs days to weeks following the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). Initially known in children and named MIS-C, recently several cases of MIS in adults have been reported to the Centers for Disease Control and Prevention (CDC), leading to the recognition of a new disease MIS in adults (MIS-A). The current treatment options include high-dose steroids, intravenous immunoglobulin (IVIG), and immunosuppressive therapy. However, the pharmacologic approach remains limited to case reports and pending official guidelines to treat cases with MIS-A. We present a case of an adult patient who had a severe inflammatory state following COVID-19 infection, who was treated with IL-1 antagonist therapy with a successful outcome.
Keywords: acute rheumatology; biologic agents; covid 19; interleukin-1β inhibitor; multisystem inflammatory syndrome in adult.
. 2022 Nov 30;14(11):e32078.
doi: 10.7759/cureus.32078. eCollection 2022 Nov.
Rapid Resolution of Post-COVID-19 Inflammatory Syndrome in an Adult With Targeted Inhibition of Interleukin-1B
Mario Felix[SUP] 1 [/SUP], Larabe Farrukh[SUP] 2 [/SUP], Simple Modi[SUP] 3 [/SUP], Ruben Peredo-Wende[SUP] 4 [/SUP]
Affiliations
- PMID: 36600829
- PMCID: PMC9803587
- DOI: 10.7759/cureus.32078
Abstract
Multisystem inflammatory syndrome (MIS) is a severe inflammatory response that occurs days to weeks following the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). Initially known in children and named MIS-C, recently several cases of MIS in adults have been reported to the Centers for Disease Control and Prevention (CDC), leading to the recognition of a new disease MIS in adults (MIS-A). The current treatment options include high-dose steroids, intravenous immunoglobulin (IVIG), and immunosuppressive therapy. However, the pharmacologic approach remains limited to case reports and pending official guidelines to treat cases with MIS-A. We present a case of an adult patient who had a severe inflammatory state following COVID-19 infection, who was treated with IL-1 antagonist therapy with a successful outcome.
Keywords: acute rheumatology; biologic agents; covid 19; interleukin-1β inhibitor; multisystem inflammatory syndrome in adult.